Technology Bundle ID
TAB-3809

Methods for Using Modulators of Extracellular Adenosine or an Adenosine Receptor To Enhance Immune Response and Inflammation

Linked ID
E-051-2002-0
Lead Inventors
Michail Sitkovsky (NIAID)
Co-Inventors
Akio Ohta (NIAID)
Development Stages
ICs
Local inflammation processes are crucially important in the host defense against pathogens and for successful immunization because proinflammatory cytokines are necessary for initiation and propagation of an immune response. However, normal inflammatory responses are eventually terminated by physiological termination mechanisms, thereby limiting the strength and duration of immune responses, especially to weak antigens. The inventors have shown that adenosine A2a and A3a receptors play a critical role in down-regulation of inflammation in vivo. They act as the physiological termination mechanism that can limit the immune response. Thus, a method was developed for inhibiting signaling through the adenosine receptor to prolong and intensify the immune response. The method involves administering either an adenosine-degrading drug or an adenosine receptor agonist. These compounds can be also used as vaccine adjuvants and treatments for accomplishing targeted tissue damage such as for tumor destruction.
Commercial Applications
  • Anti-Tumor Therapy
  • Vaccine Adjuvants for Tumors
  • Immunotherapy
Competitive Advantages
  • Use of Adenosine Receptor Agonist or Adenosine-Degrading Drug to Inhibit Signaling Through the Adenosine Receptor to Prolong and Intensify the Immune Response.
  • Use of Adenosine Receptor Agonists or Adenosine-Degrading Drugs as Vaccine Adjuvants for Tumor Destruction.

Request More Info

Licensing Contact: